ESTRO 2025 - Abstract Book

S259

Brachytherapy - Gynaecology

ESTRO 2025

Conclusion: These results suggest that DWI images as anatomical sequence without apparent diffusion coefficient mapping can led to substantial target modifications. Integrating functional imaging in the current target volume concept of IGABT needs to be further explored.

Keywords: Image guided adaptive brachytherapy, DWI_MR

References: 1. Schernberg A, Balleyguier C, Dumas I, Gouy S, Escande A, Bentivegna E, Morice P, Deutsch E, Haie-Meder C, Chargari C. Diffusion-weighted MRI in image-guided adaptive brachytherapy: Tumor delineation feasibility study and comparison with GEC-ESTRO guidelines. Brachytherapy. 2017 Sep-Oct;16(5):956-963. 2. Kumar R, Narayanan GS, Vishwanthan B, Narayanan S, Mandal S. A prospective comparative dosimetric study between diffusion weighted MRI (DWI) & T2-weighted MRI (T2W) for target delineation and planning in cervical cancer brachytherapy. Rep Pract Oncol Radiother. 2020 Nov-Dec;25(6):1011-1016.

3418

Digital Poster Variations in brachytherapy dose distribution for locally advanced cervical cancer: a dose gradient analysis Giulia Paolani 1 , Andrea Botti 1 , Valeria Trojani 1 , Roberto Sghedoni 1 , Dafne Ramundo 2 , Alice Zamagni 2 , Matteo Augugliaro 2 , Lucia Giaccherini 2 , Cinzia Iotti 2 , Mauro Iori 1 , Elisabetta Cagni 1 1 Medical Physics Unit, Azienda-USL IRCCS di Reggio Emilia, Reggio Emilia, Italy. 2 Radiation Oncology Unit, Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy Purpose/Objective: The dose variability in high-dose-rate intracavitary brachytherapy for locally advanced cervical cancer (BRT-LACC) has been widely reported in literature and is related to an array of uncertainties including variations in contouring and plan optimization. To our knowledge, no previous studies have investigated the variation of dose gradient inside the target. The purpose of the study was to investigate the role of the local dose gradient for BRT-LACC. Material/Methods: We retrospectively collected 10 patients affected by LACC treated in our institution from 2018 to 2023. All patients followed EMBRACE/EMBRACE II protocols, receiving 7Gy for 3 or 4 BRT fractions, delivered with Geneva applicator.